Healthcare Industry News: Bristol-Myers Squibb
News Release - September 27, 2007
Jeremy Levin Joins Bristol-Myers Squibb as Senior Vice President of External Science, Technology and LicensingNEW YORK, Sept. 27 (HSMN NewsFeed) -- Bristol-Myers Squibb (NYSE: BMY ) announced today that Dr. Jeremy Levin has joined the company's Research and Development organization as senior vice president, External Science, Technology and Licensing. He will report to Dr. Elliott Sigal, chief scientific officer and president, Research and Development.
"I am delighted Jeremy has joined our R&D organization at this critical juncture for Bristol-Myers Squibb, as we look to further build our robust pipeline in areas of significant unmet medical need and to transform our pharmaceutical business for the future," said Dr. Sigal. "Jeremy's extensive global network in the pharmaceutical, biotechnology and venture industries will help ensure that we remain a leader in forging creative partnerships to advance the development of novel medicines."
Prior to joining Bristol-Myers Squibb, Dr. Levin served as Global Head of Business Development and Strategic Alliances at the Novartis Institutes of Biomedical Research. In that capacity, he and his team secured hundreds of collaborations in more than 20 countries since 2003. Prior to his tenure at Novartis, Dr. Levin held leadership positions in several biotechnology companies, including Physiome Sciences, Inc. and Cadus Pharmaceutical Corporation. He also was managing director of Perseus Capital LLC, a life sciences venture fund. He has served on the executive committees and boards of several public biosciences companies, as well as the Executive Committee of BIO and the boards of the Biotechnology Institute and the New York Biotechnology Association.
"I am excited about the tremendous opportunity at Bristol-Myers Squibb," said Dr. Levin. "I am especially looking forward to working with Elliott, his team and all the outstanding people at this company. I will look to aggressively complement Bristol-Myers Squibb's world class internal team, capabilities and pipeline with the best science and medicines around the globe."
Dr. Levin received a B.A. (First Class Honors) in Zoology, and M.A. and Doctorate (D.Phil.) in Cell Biology and Chromatin Structure from the University of Oxford, as well as a Medical Degree (MB BChir) from the University of Cambridge. He practiced as a physician in internal medicine in several university hospitals, including Hammersmith Hospital in London. In 2005, Dr. Levin was awarded the Albert Einstein Award for Outstanding Achievement in the Life Sciences.
Bristol-Myers Squibb is a global pharmaceutical and related healthcare products company whose mission is to extend and enhance human life.
Source: Bristol-Myers Squibb
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.